Anti-PTPRB antibody
Specifications
| Product Cat#: | AB-06-3762 |
| Product type: | Primary antibody |
| Antigen: | PTPRB |
| Immunogen: | Recombinant protein |
| Species immunized: | Mouse |
| Isotype: | IgG2a |
| Applications: | Immunocytochemistry (1:1000) |
| Reactivity: | Mouse,Human |
| Clonality (clone number): | Monoclonal (2-A2) |
| Form: | Liquid |
| Buffer: | Tris-HCl buffer (pH7.4), 1%BSA, 40%Glycerol. Preservative: 0.05% Sodium Azide. |
| Concentration: | 2 mg/ml |
| Purity: | Protein G affinity purified |
| Storage: | Aliquot and freeze at -20℃. Avoid multiple freeze/thaw cycles. |
| Alternative names: | HPTP BETA antibody |
| HPTPB antibody | |
| Phosphacan receptor type B antibody | |
| Protein tyrosine phosphatase receptor type B antibody | |
| Protein-tyrosine phosphatase beta antibody | |
| PTPB antibody | |
| Ptprb antibody | |
| PTPRB_HUMAN antibody | |
| R PTP BETA antibody | |
| R-PTP-beta antibody | |
| Receptor-type tyrosine-protein phosphatase beta antibody | |
| RPTPB antibody | |
| Vascular endothelial protein tyrosine phosphatase antibody | |
| VE-PTP antibody |
Target information
Plays an important role in blood vessel remodeling and angiogenesis. Not necessary for the initial formation of blood vessels, but is essential for their maintenance and remodeling. Can induce dephosphorylation of TEK/TIE2, CDH5/VE-cadherin and KDR/VEGFR-2. Regulates angiopoietin-TIE2 signaling in endothelial cells. Acts as a negative regulator of TIE2, and controls TIE2 driven endothelial cell proliferation, which in turn affects blood vessel remodeling during embryonic development and determines blood vessel size during perinatal growth. Essential for the maintenance of endothelial cell contact integrity and for the adhesive function of VE-cadherin in endothelial cells and this requires the presence of plakoglobin (By similarity).
Provider
Erpantech Laboratory
